Cochrane · systematic review · CD013247
Ocrelizumab for multiple sclerosis
Lin, M, Zhang, J, Zhang, Y, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Multiple Sclerosis and Rare Diseases of the CNSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
11
No studies
2
Included studies
NR
No studies 2 · 15.4%Ungraded 0 · 0%Very low 0 · 0%Low 8 · 61.5%Moderate 3 · 23.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Ocrelizumab compared to interferon beta‐1a for relapsing‐remitting multiple sclerosis
Population: people with relapsing‐remitting multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing ≥ 1 relapse Ocrelizumab vs interferon beta‐1a | RR 0.61 [0.52, 0.73] | 2 studies · 1656 participants | Moderate Downgraded: risk of bias |
Number of participants experiencing disability progression Ocrelizumab vs interferon beta‐1a | HR 0.6 [0.43, 0.84] | 2 studies · 1656 participants | Low Downgraded: risk of bias, imprecision |
Number of participants with any adverse events Ocrelizumab vs interferon beta‐1a | RR 1 [0.96, 1.04] | 2 studies · 1651 participants | Moderate Downgraded: risk of bias |
Number of participants with any serious adverse events Ocrelizumab vs interferon beta‐1a | RR 0.79 [0.57, 1.11] | 2 studies · 1651 participants | Low Downgraded: risk of bias, imprecision |
Number of participants experiencing treatment discontinuation caused by adverse events Ocrelizumab vs interferon beta‐1a | RR 0.58 [0.37, 0.91] | 2 studies · 1651 participants | Low Downgraded: risk of bias, imprecision |
Number of participants with gadolinium‐enhancing T1 lesions on MRI Ocrelizumab vs interferon beta‐1a | RR 0.27 [0.22, 0.35] | 2 studies · 1656 participants | Low Downgraded: risk of bias, indirectness |
Number of participants with new or enlarging T2‐hyperintense lesions on MRI Ocrelizumab vs interferon beta‐1a | RR 0.63 [0.57, 0.69] | 2 studies · 1656 participants | Low Downgraded: risk of bias, indirectness |
Ocrelizumab compared to placebo for primary progressive multiple sclerosis
Population: people with primary progressive multiple sclerosis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants experiencing disability progression Ocrelizumab vs placebo | HR 0.75 [0.58, 0.98] | 1 study · 731 participants | Low Downgraded: risk of bias, imprecision |
Number of participants with any adverse events Ocrelizumab vs placebo | RR 1.06 [1.01, 1.11] | 1 study · 725 participants | Moderate Downgraded: risk of bias |
Number of participants with any serious adverse events Ocrelizumab vs placebo | RR 0.92 [0.68, 1.23] | 1 study · 725 participants | Low Downgraded: risk of bias, imprecision |
Number of participants experiencing treatment discontinuation caused by adverse event Ocrelizumab vs placebo | RR 1.23 [0.55, 2.75] | 1 study · 725 participants | Low Downgraded: risk of bias, imprecision |
Number of participants with gadolinium‐enhancing T1 lesions on MRI Ocrelizumab vs placebo | no estimate extracted | NR | No studies |
Number of participants with new or enlarging T2‐hyperintense lesions on MRI Ocrelizumab vs placebo | no estimate extracted | NR | No studies |